Danaher Corporation (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Danaher is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 22 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments…
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 58,000
- Headquarters
- Washington, DC
Similar stocks
What’s behind the score
Valuation
P/E 40.8 — lower than 25% of Healthcare peers
P/B 3.1 — lower than 57% of Healthcare peers
P/S 6.4 — lower than 27% of Healthcare peers
EV/EBITDA 23.0 — lower than 20% of Healthcare peers
EV/Revenue 7.3 — lower than 20% of Healthcare peers
PEG 1.4 — lower than 59% of Healthcare peers
FCF yield 2.7% — higher than 28% of Healthcare peers
Profitability & quality
Gross margin 58.8% — higher than 43% of Healthcare peers
Operating margin 19.8% — higher than 47% of Healthcare peers
Net margin 15.9% — higher than 67% of Healthcare peers
ROE 7.6% — higher than 37% of Healthcare peers
ROA 3.9% — higher than 21% of Healthcare peers
Free cash flow is 108% of reported net income
Financial health
Debt/equity 0.5 — lower than 74% of Healthcare peers
Current ratio 1.65 — higher than 62% of Healthcare peers
Quick ratio 1.15 — higher than 66% of Healthcare peers
Cash/debt 0.16 — higher than 31% of Healthcare peers
Debt/EBITDA 3.47 — lower than 14% of Healthcare peers
Growth
Revenue growth 5.5% YoY — higher than 30% of Healthcare peers
Earnings growth 59.7% YoY — higher than 81% of Healthcare peers
Ownership & investor activity
Payout ratio 25.7% — typical for Healthcare peers
Net insider buying, +1.4% of insider shares
Institutions net sold, -13.5% of shares held
Insiders hold 10.8% of shares outstanding
1.4% of float sold short
Momentum
Above its 50- & 200-day averages
83% of the way from its 52-week low to high